

Letter of Support for Product Development

To Whom It May Concern,

I, Martin Miller & Wines, express my support for the continued development of SNICA, a novel product offering a healthy alternative to cigarettes, vaping products, and nicotine replacement therapies, while delivering similar psychoactive effects.

This is my relationship with nicotine:

1 to 10 - 2 days

The minimum viable product of SNICA mimics the psychoactive properties of nicotine via oral delivery of its active ingredients. As an early product version, the minimum viable product, does not yet include: rapid absorption, an optimal consumption method, or taste.

I have had the opportunity to evaluate the minimum viable product of SNICA. I confirm that it mimics the psychoactive effects of nicotine without undesirable side-effects. I want to add the following comment:

No vomit smoke during 14.

Based on this experience, I confirm that I would be interested in engaging further with SNICA upon the release of its commercial version.

I believe SNICA addresses a critical need in the market and encourage its continued development. Please feel free to share this letter with relevant partners or investors to demonstrate market interest and product viability.

Signature of potential customer and date:

9/01/25

